Stem Cells SpinWAR:SCS 25 EBITDA Margin % is 3,057.14% as of Mar. 2026, which is 1005% above its 10-year median of 276.77. GuruFocus rates WAR:SCS with a GF Score™ of 25/100 and a GF Value™ of zł0.10 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 939 Biotechnology companies, Stem Cells Spin ranks better than 99.25% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Stem Cells Spin's EBITDA for the
three
months ended in Mar. 2026 was zł0.21 Mil. Stem Cells Spin's Revenue for the
three
months ended in Mar. 2026 was zł0.01 Mil. Therefore, Stem Cells Spin's EBITDA margin for the quarter that ended in Mar. 2026 was 3,057.14%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Stem Cells Spin EBITDA Margin % Related Terms
Stem Cells Spin EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Stem Cells Spin's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WAR:SCS vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, Stem Cells Spin's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Stem Cells Spin EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Stem Cells Spin's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Stem Cells Spin's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Stem Cells Spin (WAR:SCS) has a EBITDA Margin % of 3,057.14% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Stem Cells Spin and its competitors. This is 1005% above median its historical median of 276.77. Over the past decade, Stem Cells Spin's EBITDA Margin % has ranged from 78.79 to 1,816.67. According to the industry distribution chart, Stem Cells Spin ranks #7 out of 939 companies in the Biotechnology industry, placing it in the top 0.7%.
Is Stem Cells Spin's EBITDA Margin % too high?
Stem Cells Spin's current EBITDA Margin % of 3,057.14% is 1005% above median its 10-year median of 276.77. Over the past 10 years, this metric has ranged from a low of 78.79 to a high of 1,816.67. Based on the distribution chart, Stem Cells Spin ranks #7 out of 939 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Stem Cells Spin has a GF Score™ of 25/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Stem Cells Spin's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Stem Cells Spin ranks #7 out of 939 companies for EBITDA Margin %. This places Stem Cells Spin in the top 1% of its industry — outperforming the majority of peers. Historically, Stem Cells Spin's own EBITDA Margin % has ranged from 78.79 to 1,816.67 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Stem Cells Spin and its competitors. Stem Cells Spin's current EBITDA Margin % is 3,057.14%, which is 1005% above median its own 10-year median of 276.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Stem Cells Spin stock overvalued right now?
Based on GuruFocus' analysis, Stem Cells Spin (WAR:SCS) is currently considered Significantly Overvalued. The stock's GF Value™ is zł0.10, compared to a current price of zł0.40 — trading 300% above its estimated fair value. The current EBITDA Margin % is 3,057.14%, which is 1005% above median its 10-year median of 276.77. Stem Cells Spin's overall GF Score™ is 25/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Stem Cells Spin (WAR:SCS), the current EBITDA Margin % is 3,057.14% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Stem Cells Spin (WAR:SCS) Overvalued in 2026?
Based on GuruFocus' analysis, Stem Cells Spin stock appears to be overvalued.
The current stock price of zł0.40 is trading 300% above its estimated GF Value™ of zł0.10.
GuruFocus considers Stem Cells Spin to be Significantly Overvalued.
Key valuation signals for WAR:SCS:
EBITDA Margin %: 3,057.14% (1005% above median its 10-year median of 276.77)
GF Value™: zł0.10 vs. price of zł0.40 (300% above fair value)
No single metric tells the full story. See the WAR:SCS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Stem Cells Spin SA is a biotechnology company. The company is engaged in the development, production, marketing, and sale of natural regenerative products for the dermocosmetic and veterinary care markets, as well as applications for the human and veterinary medical industry. Its products include NHAC Biocervin MIC-1, Revitacell, PRS MIC-1, and Velvetyna.
25GF Score
Get the complete analysis for WAR:SCS
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:SCS has been successfully added to your 
